Team:UCSF/Parts

From 2010.igem.org

(Difference between revisions)
Line 32: Line 32:
{
{
margin-left:35px;
margin-left:35px;
-
width:80%;
+
width:75%;
border-collapse:collapse;
border-collapse:collapse;
}
}
Line 69: Line 69:
<!-- add device list below -->
<!-- add device list below -->
-
<p>During the summer we built the following devices under the BioBrick standard <a href="https://2009.igem.org/Judging/Variance/UCSF">RFC28</a> (see more info <a href="http://dspace.mit.edu/bitstream/handle/1721.1/46721/BBFRFC28.pdf">here</a>), which was developed by the UCSF team in 2009 and was approved by the Registry of Parts.  However, this year the Registry does not accept RFC28.  Due to time constrains, we could not move all of these parts into pSB1C3 and submit them as we had planned.</p>
+
<p>During the summer we built the following devices under the BioBrick standard <a href="https://2009.igem.org/Judging/Variance/UCSF">RFC28</a> (see more info <a href="http://dspace.mit.edu/bitstream/handle/1721.1/46721/BBFRFC28.pdf">here</a>), which was developed by the UCSF team in 2009 and was approved by the Registry of Parts.  However, this year the Registry does not accept RFC28.  Due to time constrains, we could not move all of these parts into pSB1C3 and submit them as we had planned.</p><br>
<table id="customers">
<table id="customers">
  <tr>
  <tr>
-
   <td>Designed by</td>
+
   <th>Designed by</th>
-
   <td>Ligated parts</td>
+
   <th>Ligated parts</th>
-
   <td>Function</td>
+
   <th>Function</th>
  </tr>
  </tr>
  <tr>
  <tr>
Line 137: Line 137:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Carmen</td>
   <td>Carmen</td>
   <td>antiMESOCAR-CD3Z-STOP</td>
   <td>antiMESOCAR-CD3Z-STOP</td>
Line 147: Line 148:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Carmen</td>
   <td>Carmen</td>
   <td>antiMESOCAR-KIR3DL2-STOP</td>
   <td>antiMESOCAR-KIR3DL2-STOP</td>
Line 157: Line 159:
   <td>Inhibition</td>
   <td>Inhibition</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiMESOCAR-LFA1-DAP10</td>
   <td>antiMESOCAR-LFA1-DAP10</td>
Line 167: Line 170:
   <td>Logic Gate Signaling</td>
   <td>Logic Gate Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiCD19CAR-mDAP10 M88Q-STOP</td>
   <td>antiCD19CAR-mDAP10 M88Q-STOP</td>
Line 177: Line 181:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Lianna</td>
   <td>Lianna</td>
   <td>antiMESOCAR-OX40-CD3z</td>
   <td>antiMESOCAR-OX40-CD3z</td>
Line 187: Line 192:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Carmen</td>
   <td>Carmen</td>
   <td>antiMESOCAR-ICOS-DAP10</td>
   <td>antiMESOCAR-ICOS-DAP10</td>
Line 197: Line 203:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Carmen</td>
   <td>Carmen</td>
   <td>antiCD19CAR-ICOS-DAP10</td>
   <td>antiCD19CAR-ICOS-DAP10</td>
Line 207: Line 214:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiMESOCAR-CD3z-CD3z</td>
   <td>antiMESOCAR-CD3z-CD3z</td>
Line 217: Line 225:
   <td>Logic Gate Negative Control</td>
   <td>Logic Gate Negative Control</td>
  </tr>
  </tr>
-
  <tr>
+
   
 +
<tr class="alt">
   <td>Connor</td>
   <td>Connor</td>
   <td>antiCD19CAR-KIR3DL1-STOP</td>
   <td>antiCD19CAR-KIR3DL1-STOP</td>
Line 227: Line 236:
   <td>Inhibition</td>
   <td>Inhibition</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiMESOCAR-DAP10-STOP</td>
   <td>antiMESOCAR-DAP10-STOP</td>
Line 237: Line 247:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Lianna</td>
   <td>Lianna</td>
   <td>antiCD19CAR-OX40-CD3z</td>
   <td>antiCD19CAR-OX40-CD3z</td>
Line 247: Line 258:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Carmen</td>
   <td>Carmen</td>
   <td>antiCD19CAR-SLAMF1-DAP10</td>
   <td>antiCD19CAR-SLAMF1-DAP10</td>
Line 257: Line 269:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>John</td>
   <td>John</td>
   <td>antiMESOCAR-SLAMF1-CD3z</td>
   <td>antiMESOCAR-SLAMF1-CD3z</td>
Line 267: Line 280:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Lianna</td>
   <td>Lianna</td>
   <td>antiCD19CAR-FcRg-STOP</td>
   <td>antiCD19CAR-FcRg-STOP</td>
Line 277: Line 291:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Lianna</td>
   <td>Lianna</td>
   <td>antiCD19CAR-CD28-STOP</td>
   <td>antiCD19CAR-CD28-STOP</td>
Line 287: Line 302:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Lianna</td>
   <td>Lianna</td>
   <td>antiMESOCAR-ICOS-STOP</td>
   <td>antiMESOCAR-ICOS-STOP</td>
Line 297: Line 313:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Lianna</td>
   <td>Lianna</td>
   <td>antiCD19CAR-LFA1-STOP</td>
   <td>antiCD19CAR-LFA1-STOP</td>
Line 307: Line 324:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiCD19CAR-LFA1-CD3z</td>
   <td>antiCD19CAR-LFA1-CD3z</td>
Line 317: Line 335:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiMESOCAR-SLAMF3-CD3z</td>
   <td>antiMESOCAR-SLAMF3-CD3z</td>
Line 327: Line 346:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiMESOCAR-Ly49-STOP</td>
   <td>antiMESOCAR-Ly49-STOP</td>
Line 337: Line 357:
   <td>Negative Feedback</td>
   <td>Negative Feedback</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td>antiCD19CAR-OX40-STOP</td>
   <td>antiCD19CAR-OX40-STOP</td>
Line 347: Line 368:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Crystal</td>
   <td>Crystal</td>
   <td> antiCD19CAR-CD3g-CD3z</td>
   <td> antiCD19CAR-CD3g-CD3z</td>
Line 357: Line 379:
   <td>Stronger Signaling</td>
   <td>Stronger Signaling</td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Min</td>
   <td>Min</td>
   <td>GZMB-eGFP-CDMPR</td>
   <td>GZMB-eGFP-CDMPR</td>
Line 367: Line 390:
   <td>Localization to Cytoxic Granules </td>
   <td>Localization to Cytoxic Granules </td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Min</td>
   <td>Min</td>
   <td>GZMB-eGFP-LAMP</td>
   <td>GZMB-eGFP-LAMP</td>
Line 377: Line 401:
   <td>Localization to Cytoxic Granules </td>
   <td>Localization to Cytoxic Granules </td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Min</td>
   <td>Min</td>
   <td>GZMB-eGFP-Ymotif</td>
   <td>GZMB-eGFP-Ymotif</td>
Line 387: Line 412:
   <td>Localization to Cytoxic Granules </td>
   <td>Localization to Cytoxic Granules </td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Min</td>
   <td>Min</td>
   <td>GZMM-eGFP-CDMPR</td>
   <td>GZMM-eGFP-CDMPR</td>
Line 397: Line 423:
   <td>Localization to Cytoxic Granules </td>
   <td>Localization to Cytoxic Granules </td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Min</td>
   <td>Min</td>
   <td>GZMM-eGFP-LAMP</td>
   <td>GZMM-eGFP-LAMP</td>
Line 407: Line 434:
   <td>Localization to Cytoxic Granules </td>
   <td>Localization to Cytoxic Granules </td>
  </tr>
  </tr>
-
  <tr>
+
 
 +
  <tr class="alt">
   <td>Min</td>
   <td>Min</td>
   <td>GZMM-eGFP-Ymotif</td>
   <td>GZMM-eGFP-Ymotif</td>

Revision as of 23:16, 27 October 2010


Parts

<groupparts>iGEM010 UCSF</groupparts>

During the summer we built the following devices under the BioBrick standard RFC28 (see more info here), which was developed by the UCSF team in 2009 and was approved by the Registry of Parts. However, this year the Registry does not accept RFC28. Due to time constrains, we could not move all of these parts into pSB1C3 and submit them as we had planned.


Designed by Ligated parts Function
Carmen Old antiMesoCAR-LFA1-Dap10 Stronger Signaling
John antiCD19CAR-DAP10-STOP Positive Control
Hannah antiCD19CAR-mDAP10y85F-STOP Stronger Signaling
Lianna antiCD19CAR-mDAP10N87Q-STOP Negative Control
Sam antiMESOCAR-mDAP10N87Q-STOP Logic Gate Signaling
Crystal antiMESOCAR-DAP10-CD3Z Stronger Signaling
Crystal antiMESOCAR- LFA1-CD3z Stronger Signaling
Crystal antiMESOCAR-DAP10-DAP10 Stronger Signaling
Sam antiCD19CAR-DAP10-CD3z Stronger Signaling
Sam antiCD19CAR-DAP10-Dap10 Stronger Signaling
Sam antiCD19CAR-CD3z-CD3z Stronger Signaling
Carmen antiMESOCAR-CD3Z-STOP Positive Control
Carmen antiCD19-CD3z-STOP Stronger Signaling
Carmen antiMESOCAR-KIR3DL2-STOP Inhibition
Carmen antiCD19CAR-KIR3DL2-STOP Inhibition
Crystal antiMESOCAR-LFA1-DAP10 Stronger Signaling
Crystal antiMESOCAR-mDAP10 M88Q-STOP Logic Gate Signaling
Crystal antiCD19CAR-mDAP10 M88Q-STOP Logic Gate Signaling
Lianna antiMESOCAR-OX40-Dap10 Stronger Signaling
Lianna antiMESOCAR-OX40-CD3z Stronger Signaling
Carmen antiMESOCAR-FcRg-DAP10 Stronger Signaling
Carmen antiMESOCAR-ICOS-DAP10 Stronger Signaling
Carmen antiCD19CAR-FcRg-DAP10 Stronger Signaling
Carmen antiCD19CAR-ICOS-DAP10 Stronger Signaling
Carmen antiCD19CAR-LFA1-DAP10 Stronger Signaling
Crystal antiMESOCAR-CD3z-CD3z Stronger Signaling
Lianna antiMESOCAR-mDAP10Y85F-STOP Logic Gate Negative Control
Connor antiCD19CAR-KIR3DL1-STOP Inhibition
Connor antiMESOCAR-KIR3DL1-STOP Inhibition
Crystal antiMESOCAR-DAP10-STOP Stronger Signaling
Lianna antiCD19CAR-OX40-DAP10 Stronger Signaling
Lianna antiCD19CAR-OX40-CD3z Stronger Signaling
Carmen antiCD19CAR-SLAMF1-CD3z Stronger Signaling
Carmen antiCD19CAR-SLAMF1-DAP10 Stronger Signaling
Carmen antiCD19CAR-SLAMF5-DAP10 Stronger Signaling
John antiMESOCAR-SLAMF1-CD3z Stronger Signaling
John antiMESOCAR-SLAMF5-DAP10 Stronger Signaling
Lianna antiCD19CAR-FcRg-STOP Stronger Signaling
Lianna antiCD19CAR-ICOS-STOP Stronger Signaling
Lianna antiCD19CAR-CD28-STOP Stronger Signaling
Lianna antiMESOCAR-FcRg-STOP Stronger Signaling
Lianna antiMESOCAR-ICOS-STOP Stronger Signaling
Lianna antiMESOCAR-CD28-STOP Stronger Signaling
Lianna antiCD19CAR-LFA1-STOP Stronger Signaling
Lianna antiMESOCAR-LFA1-STOP Stronger Signaling
Crystal antiCD19CAR-LFA1-CD3z Stronger Signaling
Crystal antiMESOCAR-OX40-STOP Stronger Signaling
Crystal antiMESOCAR-SLAMF3-CD3z Stronger Signaling
Crystal antiMESOCAR- CD3g-CD3z Stronger Signaling
Crystal antiMESOCAR-Ly49-STOP Stronger Signaling
Crystal antiMESOCAR-NKG2A-STOP Negative Feedback
Crystal antiCD19CAR-OX40-STOP Stronger Signaling
Crystal antiCD19CAR-SLAMF3-CD3z Stronger Signaling
Crystal antiCD19CAR-CD3g-CD3z Stronger Signaling
Crystal antiCD19CAR-FcRg-CD3z Stronger Signaling
Min GZMB-eGFP-CDMPR Localization to Cytoxic Granules
Min GZMB-eGFP-GILT Localization to Cytoxic Granules
Min GZMB-eGFP-LAMP Localization to Cytoxic Granules
Min GZMB-eGFP-LIMP Localization to Cytoxic Granules
Min GZMB-eGFP-Ymotif Localization to Cytoxic Granules
Min GZMB-eGFP-STP Localization to Cytoxic Granules
Min GZMM-eGFP-CDMPR Localization to Cytoxic Granules
Min GZMM-eGFP-GILT Localization to Cytoxic Granules
Min GZMM-eGFP-LAMP Localization to Cytoxic Granules
Min GZMM-eGFP-LIMP Localization to Cytoxic Granules
Min GZMM-eGFP-Ymotif Localization to Cytoxic Granules
Min GZMM-eGFP-STP Localization to Cytoxic Granules

Retrieved from "http://2010.igem.org/Team:UCSF/Parts"